Plasminogen

Summary

Plasminogen (CHEMBL2108131) is a phase-3 clinical-stage unknown; indicated across 2 conditions including stroke disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108131
Name	Plasminogen
Type	Unknown
Max phase	3

Also known as: Human plasminogen, Plasma trypsinogen, Plasminogen, Profibrinolysin, PLASMINOGEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stroke disorder	3	MONDO:0005098	EFO:0000712

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
Not specified	3
PHASE2/PHASE3	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01554956	PHASE2/PHASE3	COMPLETED	Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
NCT02690714	PHASE2/PHASE3	COMPLETED	A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
NCT06381661	PHASE2	NOT_YET_RECRUITING	Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
NCT01222117	PHASE2	COMPLETED	A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
NCT02312180	PHASE1	COMPLETED	A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
NCT04586062	Not specified	AVAILABLE	Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
NCT03265171	Not specified	NO_LONGER_AVAILABLE	A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
NCT04170647	Not specified	UNKNOWN	Efficacy of Intravenous Tissue-type Plasminogen Activator on Acute Ischemic Stroke Patients With Large Vessel Occlusions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).